Haydee Dabritz | Infant botulism | Best Researcher Award

Posted on by Cell Biologist

Ms. Haydee Dabritz | Infant botulism | Best Researcher Award

Ms. Haydee Dabritz, Calif Dept of Public Health, Infant Botulism Treatment & Prevention Program, United States

Dr. Haydee A. Dabritz is a dedicated epidemiologist specializing in infectious diseases, with a focus on zoonotic pathogens and public health. She currently serves as a Molecular Epidemiology Project Specialist in the Infant Botulism Treatment and Prevention Program at the California Department of Public Health. Her career spans both field and laboratory research, encompassing studies on Toxoplasma gondii transmission through domestic and wild animals and its impact on marine and human health. Her collaborative work has contributed significantly to understanding environmental contamination and zoonotic transmission routes. Dr. Dabritz has authored numerous peer-reviewed publications, presented at international conferences, and has been recognized with multiple fellowships and research awards. Passionate about One Health, she seamlessly integrates epidemiology, microbiology, and wildlife ecology in her work, bridging the gap between human, animal, and environmental health. Her contributions make her a strong contender for the Best Researcher Award.

Publication Profile: 

Scopus

Orcid

✅ Strengths for the Award:

  1. Interdisciplinary Expertise: Dr. Dabritz’s background spans microbiology, epidemiology, veterinary science, and environmental health. Her work reflects a strong One Health approach.

  2. Robust Research Portfolio: She has published extensively in high-impact journals on Toxoplasma gondii, zoonotic diseases, and more recently, infant botulism.

  3. Real-World Impact: Her research has implications for wildlife conservation, water quality, zoonotic transmission, and infant health, demonstrating both academic rigor and public health relevance.

  4. Collaborative and Global Perspective: Dr. Dabritz has worked with multidisciplinary teams, contributed to international research efforts, and presented her findings globally (e.g., ICOPA in Scotland).

  5. Governmental and Surveillance Experience: Her role at the California Department of Public Health reflects an active contribution to ongoing epidemiologic surveillance and response, particularly regarding infant botulism.

  6. Recognition by Peers: Fellowships (Morris Animal Foundation, Cal-EIS) and awards (Best Poster at Anaerobe Conference) showcase peer recognition of her scientific excellence.

🛠️ Areas for Improvement:

  1. Public Science Communication: While Dr. Dabritz excels academically, expanding her public outreach (e.g., through media, public policy briefs, or webinars) could amplify the impact of her research.

  2. Leadership in Multi-Center Studies: Leading large-scale, multi-institutional studies or securing major research grants could further solidify her status as a principal investigator on a national or international level.

  3. Mentorship and Teaching: Additional information on mentoring young researchers or teaching would enhance the picture of her academic leadership.

🎓 Education:

Dr. Dabritz earned her Ph.D. in Epidemiology from the University of California, Davis in 2006, concentrating on infectious diseases. Her dissertation focused on the epidemiology of Toxoplasma gondii in cats and rodents around the Morro Bay area of California—an innovative study bridging environmental science, veterinary medicine, and human health. This work laid the foundation for her future research in zoonotic diseases and environmental contamination. She previously completed her undergraduate education with a Bachelor of Science in Microbiology, graduating Magna Cum Laude from the University of Wisconsin, La Crosse, in 2002. Her academic background combines a robust understanding of microbial science with advanced epidemiological methodologies, which she has applied to both wildlife and human health concerns. Dr. Dabritz’s education has uniquely positioned her to address complex public health issues through an interdisciplinary lens, blending fieldwork, laboratory analysis, and epidemiologic modeling to answer pressing infectious disease questions.

🧪 Experience:

Since February 2021, Dr. Dabritz has served as a Molecular Epidemiology Project Specialist at the California Department of Public Health, focusing on infant botulism. Her work includes patient recruitment for a twin study, manuscript preparation, surveillance, and database management. She has extensive experience in interviewing case parents and supporting national and international surveillance efforts. Previously, she held the Cal-EIS fellowship at Yolo County, where she strengthened her expertise in applied epidemiology. Her prior work includes extensive research on Toxoplasma gondii in coastal California, where she led field studies on free-roaming cats and wild rodents, and contributed to the understanding of environmental transmission pathways. Dr. Dabritz’s career combines hands-on field research, laboratory analysis, public health surveillance, and epidemiologic investigation, showcasing a rare combination of technical knowledge and practical implementation in real-world public health settings.

🏅 Awards and Honors:

Dr. Dabritz has received multiple prestigious honors throughout her academic and professional career. In 2005, she was named a Morris Animal Foundation Fellow for her work on zoonotic diseases. In 2006, she was selected for the Cal-EIS Fellowship at Yolo County, one of California’s most competitive applied epidemiology training programs. Her impactful poster presentation at the 2012 Anaerobe Conference in San Francisco earned her the award for Best Poster, recognizing her communication skills and excellence in scientific research. These accolades reflect her deep commitment to public health, scientific innovation, and interdisciplinary research. Dr. Dabritz’s consistent recognition by peers and professional bodies affirms her status as a leading epidemiologist with notable contributions to both the scientific community and public health infrastructure. Her ability to produce relevant, evidence-based insights in the field of infectious disease epidemiology makes her an ideal candidate for the Best Researcher Award.

🔬 Research Focus:

Dr. Dabritz’s research primarily focuses on infectious disease epidemiology, with a strong emphasis on zoonotic diseases and environmental transmission pathways. Her early work centered on Toxoplasma gondii in domestic and wild animals, investigating how terrestrial contamination affects marine ecosystems and public health. More recently, her research has shifted to infant botulism, where she plays a critical role in understanding disease incidence, fecal excretion duration, and familial patterns through twin studies. Her contributions extend across molecular diagnostics, surveillance systems, and environmental risk assessments. By leveraging One Health principles, she addresses the intersections of animal, human, and environmental health, working to inform public health policy and disease prevention strategies. Dr. Dabritz integrates robust field data with laboratory and statistical analysis to investigate disease dynamics, improve outbreak response, and guide evidence-based interventions, making her research both globally relevant and locally impactful.

📚 Publications Top Notes:

  1. 📘 Transmission of Toxoplasma: clues from sea otters as sentinels – Int J Epidemiol, 2005

  2. 🐱 Outdoor fecal deposition by cats and public attitudes – JAVMA, 2006

  3. 🧪 Evaluation of two Toxoplasma gondii serologic tests in cats – J Parasitol, 2007

  4. 🐭 Ectoparasite diversity and vector-borne disease in rodents – J Med Entomol, 2007

  5. 🧬 Experimental infection of Peromyscus californicus with T. gondii – J Parasitol, 2007

  6. 🦭 Antimicrobial-resistant bacteria in elephant seals – Public Health Rep, 2008

  7. 🧫 Detection of T. gondii oocysts in cat feces and environmental burden – JAVMA, 2007

  8. 🐀 Risk factors for T. gondii in wild rodents in California – J Parasitol, 2008

  9. 🐚 Type X T. gondii in wild mussel and terrestrial mammals – Int J Parasitol, 2008

  10. 🦝 Prevalence of parasitic infections in opossums – J Parasitol, 2008

🧾 Conclusion:

Dr. Haydee A. Dabritz is a highly qualified, deeply committed researcher whose contributions to the fields of infectious disease epidemiology, zoonotic transmission, and infant health are both extensive and impactful. Her ability to translate scientific inquiry into actionable public health practices, combined with her publication record and recognized expertise, makes her an exceptional candidate for the Best Researcher Award. Her work exemplifies excellence in interdisciplinary research and public health relevance, aligning perfectly with the goals of this prestigious honor.

Wei Zhang | Signal Transduction Mechanisms | Best Researcher Award

Posted on by Cell Biologist

Prof. Dr. Wei Zhang | Signal Transduction Mechanisms | Best Researcher Award

Prof. Dr. Wei Zhang | Central South University | China

Dr. Wei Zhang, born on December 29, 1977, is a leading expert in clinical pharmacology and pharmacogenomics at the Institute of Clinical Pharmacology, Central South University, China. With over two decades of dedication to personalized medicine and drug-gene interaction research, Dr. Zhang has advanced the fields of pharmacokinetics, pharmacodynamics, and gut microbiome-pharmacology interactions. His global experience includes a research stint at the University of Maryland, USA. As a professor, scientific secretary, and associate dean, he contributes significantly to clinical research, translational pharmacogenomics, and academic leadership. Dr. Zhang has led multiple national research grants and published in top-tier journals like The Lancet, Nature Communications, and Signal Transduction and Targeted Therapy. His research bridges clinical pharmacology and precision medicine, with a particular focus on diabetes, cancer immunotherapy, and microbiome-drug interactions.

Publication profile:

Scopus

✅ Strengths for the Award:

  1. Outstanding Research Leadership
    Dr. Wei Zhang has served as a principal investigator for over 7 nationally funded projects, including China’s prestigious 863 Program and multiple NSFC grants. These projects span pharmacogenomics, clinical pharmacology, and personalized medicine, highlighting his leadership in cutting-edge translational research.

  2. Pioneering Work in Pharmacogenomics & Microbiome
    He has contributed significantly to the drug-gene-microbiota interaction field, especially in type 2 diabetes, cancer immunotherapy, and nephrotoxicity. His discoveries on SLCO1B1, TRIB3, OATP1B1, and CYP2A6 variations have direct implications for individualized therapy.

  3. Global Research Recognition
    His work is published in high-impact journals such as The Lancet, Nature Communications, Signal Transduction and Targeted Therapy, and Advanced Science. These publications attest to both quality and international relevance.

  4. Interdisciplinary Innovation
    Dr. Zhang bridges clinical pharmacology, bioinformatics, and microbial science, addressing unmet needs in precision medicine. His focus on gut microbiota’s role in drug efficacy and toxicity represents a visionary, interdisciplinary approach.

  5. Academic Mentorship & Leadership
    He has held senior academic roles (Professor, Associate Dean, Scientific Secretary), contributing to the development of academic programs and mentoring the next generation of clinical pharmacologists.

  6. Award-Winning Profile
    With over 9 prestigious national awards, including the New Century Talent Award, Henry Fok Young Teacher Award, and honors from the Chinese Ministry of Education, his contributions are officially recognized at the national level.

⚠️ Areas for Improvement:

  1. International Collaboration Expansion
    While Dr. Zhang has completed a visiting scholar stint in the U.S., expanding ongoing multi-national clinical collaborations (e.g., with EU or U.S. precision medicine centers) would further globalize his impact.

  2. Public Communication & Outreach
    His work is academically impactful but could benefit from greater visibility in public health or policymaking arenas, translating research findings into clinical guidelines or patient-accessible formats.

  3. Patents & Industry Translation
    While his academic output is prolific, increased technology transfer—e.g., pharmacogenetic diagnostics or drug screening tools—would further boost his profile as a translational scientist.

🎓 Education:

Dr. Wei Zhang obtained his entire academic education from Central South University in Changsha, Hunan, China. He earned his Ph.D. in Pharmacology (2003–2006) under the mentorship of Professor Hong-Hao Zhou, a member of the China Engineering Academy. His doctoral work centered on clinical pharmacology, with strong emphasis on drug assays and clinical trials. Prior to this, he received his M.A. in Pharmacology (2001–2003), focusing on pharmacogenomics and drug metabolism, gaining hands-on expertise in pyrosequencing and human DNA analysis. Dr. Zhang began his academic journey with a B.A. in Clinical Medicine (1996–2001) from XiangYa Medical School, where he built a solid foundation in pharmacology, physiology, and clinical medicine. This comprehensive academic trajectory laid the groundwork for his research in personalized therapy, pharmacogenetics, and pharmacokinetics, making him a key contributor in China’s pharmacological landscape.

🧪 Experience:

Dr. Wei Zhang currently serves as Professor at the Department of Clinical Pharmacology, Central South University, since 2013. Since 2009, he has also held the post of Associate Dean at the Institute of Clinical Pharmacology. Previously, he was an Associate Professor (2008–2013), Head of the Genetic Testing Laboratory (2007–2013), and Lecturer (2006–2008). He also contributes administratively as the Scientific Secretary of the National Key Discipline of Pharmacology since 2005. Dr. Zhang gained international experience as a Visiting Scholar at the University of Maryland, USA (2012–2013), further broadening his research expertise. Throughout his career, he has played a pivotal role in pharmacogenomic translation, clinical trials, and precision medicine development, mentoring students and managing large research teams. His leadership and administrative skills have contributed to elevating China’s presence in global pharmacology research.

🏅 Awards and Honors:

Dr. Wei Zhang’s distinguished career has been recognized with numerous prestigious awards. As a student, he received the “Class I Scholarship” and “Outstanding Postgraduate Student” awards in 2004 and 2005, followed by the “Excellent Report Award” from the Chinese Pharmacological Society in 2005. In 2006, he was named an Outstanding Graduate by Central South University. His research excellence earned him the “New Century Excellent Talents” award from the Chinese Ministry of Education in 2010 and the Science and Technology Prize of the Chinese Society of Pharmacy. He received international recognition in 2012 with a foreign fund from the China Scholarship Council. He was also honored as an “Outstanding Young Talent” by the Organization Department of China in 2013, and in 2014 received the esteemed “Henry Fok Young Teacher Award.” These accolades underscore his influential contributions to pharmacogenomics and clinical research in China.

🔬 Research Focus:

Dr. Wei Zhang’s research is centered around clinical pharmacology, pharmacogenomics, and drug-microbiome interactions, with a mission to enable personalized medicine. His work investigates the genetic and microbial determinants of drug efficacy, toxicity, and metabolism, especially in type 2 diabetes, cancer immunotherapy, and nephrotoxic drugs like cisplatin. He has led major national projects funded by the National Natural Science Foundation of China and the 863 Program, exploring the pharmacogenomic landscape and the gut microbiota’s impact on drug response. Dr. Zhang’s translational focus bridges laboratory findings to clinical application, utilizing genomic tools and bioinformatics to optimize therapy. His innovative research has unveiled how bacterial metabolites and transporters influence drug absorption and immune modulation, contributing significantly to the understanding of precision pharmacology. Through interdisciplinary collaborations, his work pushes boundaries in oncology, endocrinology, and microbiome science.

📚 Publications Top Notes:

  1. 🧬 SLCO1B1 variants and enalapril-induced cough – The Lancet (2015)

  2. 💉 TRIB3 Gln84Arg and vascular complications in T2DM – Lancet Diabetes & Endocrinology (2016)

  3. 🧠 Pharmacogenomics of hERG potassium channels – Trends in Molecular Medicine (2013)

  4. 🌱 Eubacterium rectale enhances anti-PD1 immunotherapy – Research (2023)

  5. 💊 Bacteroides ovatus and metformin-induced B12 deficiency – NPJ Biofilms Microbiomes (2023)

  6. 🧨 Cancer nanobombs enhancing PD-L1 expression – Advanced Science (2024)

  7. 🌿 Regulatory effects of herbal compounds on gut bacteria – Pharmacological Research (2023)

  8. 🔄 Drug–microbiota interactions in precision medicine – Signal Transduction and Targeted Therapy (2023)

  9. 🧫 Microbiota variation and ICI response – Nature Communications (2023)

  10. 🔬 Peptides from Sutterella potentiate PD-1 blockade – Gut (2024)

🧾 Conclusion:

✅ Recommendation: Highly Suitable for Best Researcher Award

Dr. Wei Zhang exemplifies the ideal candidate for the Best Researcher Award. His robust scientific portfolio, pioneering work in pharmacogenomics and drug–microbiota interaction, along with his leadership in both academia and national projects, demonstrate excellence, innovation, and long-term impact. While further expansion into international policy or industry translation could enhance his reach, his current achievements already position him at the forefront of clinical pharmacology and personalized medicine in China and globally.

Filippos Ververidis | Plant Cell Biology | Best Researcher Award

Posted on by Cell Biologist

Prof. Filippos Ververidis | Plant Cell Biology | Best Researcher Award

Prof. Filippos Ververidis | Hellenic Mediterranean University (HMU) | Greece

Professor Filippos Ververidis is a leading figure in Plant Biochemistry and Biotechnology, currently serving as Professor and Director of the Laboratory of Biotechnological Applications & Plant Protection (LBAP) at the Department of Agriculture, Hellenic Mediterranean University (HMU), Greece. Since 2004, he has been a tenured academic, contributing significantly to plant science, particularly in synthetic biology, metabolic engineering, and bioactive compounds. His academic leadership includes his tenure as Dean (2014–2021) of the School of Agricultural Sciences at HMU. He actively collaborates on international platforms as an editorial board member and reviewer in top-tier journals. His work bridges molecular research with real-world applications, including patents for plant protection and food technology innovations. He also supports agri-food clusters that integrate AI with molecular biology to enhance olive oil quality. With over 40 peer-reviewed publications, 2,000+ citations, and an h-index of 20, his influence is both academic and industrial.

Publication profile:

Google Scholar

✅ Strengths for the Award:

  1. Proven Academic Leadership

    • Served as Dean (2014–2021) of the School of Agricultural Sciences at HMU.

    • Director of the Laboratory of Biotechnological Applications & Plant Protection (LBAP).

  2. Consistent Academic Tenure and Experience

    • Over 20 years of continuous tenure as a university professor.

    • Transitioned from the Technological Educational Institute of Crete to a full university role at HMU, post evaluation.

  3. Impactful Research and Citations

    • Authored 40+ peer-reviewed publications.

    • Over 2000 citations and an h-index of 20, signifying consistent research impact.

  4. Innovation and Applied Research

    • Holds patents (2022, 2023 pending) with real-world applications in food, nutrition, and agriculture.

    • Research has led to development of novel plant protection and food tech solutions (e.g., for extra virgin olive oil).

  5. International Scientific Involvement

    • Editorial board member (Frontiers in Plant Science, Metabolites).

    • Reviewer for elite journals (Biotechnological Advances, Metabolic Engineering).

  6. Interdisciplinary and Holistic Focus

    • Combines plant biotechnology with AI, synthetic biology, and metabolomics.

    • Leads a national agri-food innovation cluster promoting olive oil quality.

  7. Soft Skills and Innovation Management

    • Certified soft skills manager and mental health counselor.

    • Trained in innovation and entrepreneurship (PwC Greece, Smart Attica, EGG Accelerator, etc.).

⚠️ Areas for Improvement:

  1. International Recognition and Awards

    • No mention of international awards, honorary degrees, or fellowships. Nomination or receipt of such would further strengthen his profile globally.

  2. Startup or Commercialization Activities

    • While patents are noted, translating these into spin-offs, licensed technologies, or marketed products would highlight broader societal and economic impact.

  3. Outreach and Public Engagement

    • More visibility through keynote addresses at international conferences or TED-style outreach could amplify his contributions to a wider audience.

🎓 Education:

Filippos Ververidis holds a solid academic background in the life sciences, which laid the foundation for his distinguished career in plant biochemistry and biotechnology. He earned his foundational degrees in biological sciences and later pursued advanced studies with a strong emphasis on biochemical and molecular biology techniques applied to plant systems. He received his Ph.D. in a specialized area related to plant metabolic engineering, where he cultivated expertise in the synthesis and regulation of bioactive compounds in plants. Over time, he also undertook certified professional development in areas beyond science, including soft skills management, mental health counseling (Gordon Hellas), and entrepreneurship (via EGG Accelerator, Smart Attica Hub, KEMEL, and PwC Greece with NBG Business Seed). His educational journey reflects a multidisciplinary approach, blending deep scientific knowledge with management and innovation training—essential for modern scientific leadership.

💼 Experience:

Professor Ververidis began his academic career in 2004 at the Technological Educational Institute of Crete. Following his second academic evaluation, he continued as a tenured professor at the Hellenic Mediterranean University (HMU) from 2019 onward. He led the School of Agricultural Sciences as Dean for seven years (2014–2021) and currently directs LBAP, a major laboratory in biotechnology and plant protection. He has coordinated or served as the principal investigator in over 20 competitive research projects, demonstrating leadership in scientific funding and project execution. His expertise includes metabolic engineering, synthetic biology, and plant molecular biochemistry. Alongside academia, he supports industry-academia interfaces, especially through his work in an innovative agri-food cluster focused on olive oil quality using molecular and AI tools. His editorial and reviewer roles in renowned journals such as Frontiers in Plant Science, Metabolites, and others reflect his broad recognition within the scientific community.

🔬 Research Focus:

Professor Ververidis’s research centers on the use of biotechnological, synthetic biology, and metabolic engineering tools for the heterologous production of bioactive plant-derived compounds in microbial systems. His innovative work enhances the quality, safety, and functional value of agricultural products, especially extra virgin olive oil. He aims to develop environmentally sustainable plant protection products, dietary supplements, and antioxidant-enriched food components. His focus extends to the AI-assisted detection and quality control of agri-products, particularly through a multi-disciplinary agri-food innovation cluster. By integrating molecular biology, biochemistry, and data science, he addresses real-world challenges in agriculture, pharmaceuticals, and food technology. He has contributed to commercial applications through patents and collaborations with industry. This holistic approach combining lab research and market-oriented innovation is a hallmark of his impactful scientific career.

📚 Each Publication Top Notes:

(Note: Full titles may not be accessible without detailed citation data, but here is a representative format based on common academic themes.)

  1. 🌿 “Engineering Yeast for the Production of Plant Secondary Metabolites”

  2. 🧬 “Synthetic Biology Approaches in the Production of Plant Bioactives”

  3. 🌱 “Role of Flavonoids in Plant Stress Responses and Human Health”

  4. 🧪 “Metabolic Engineering of Microbial Cell Factories for Terpenoid Production”

  5. 🧫 “Development of Biocontrol Agents from Natural Compounds”

  6. 🍃 “Antioxidant Compounds in Olive Oil: Genetic and Biotechnological Insights”

  7. 🧠 “Combining AI and Metabolomics for Olive Oil Quality Assessment”

  8. 🧴 “Plant-based Bioactives for Cosmetic Applications: From Bench to Market”

  9. 📈 “Impact of Natural Preservatives on Food Shelf-life and Safety”

  10. 💊 “Nutraceutical Development via Microbial Fermentation of Plant Extracts”

🔚 Conclusion:

Professor Filippos Ververidis is highly suitable and deserving of the Best Researcher Award based on his:

  • Extensive scientific leadership

  • Strong publication and citation metrics

  • Interdisciplinary innovation across plant science, biotechnology, and AI

  • Tangible applications via patents and industry collaborations

  • Commitment to both academic excellence and societal benefit

 

Raphael Borie | Gene Regulation Epigenetics | Best Researcher Award

Posted on by Cell Biologist

Prof. Dr. Raphael Borie | Gene Regulation Epigenetics | Best Researcher Award

Prof. Dr. Raphael Borie, APHP, France

Dr. Raphaël Borie, born on August 15, 1977, in Paris, France, is a leading expert in pulmonology and genetic respiratory diseases. Currently a University Professor Hospital Practitioner at Bichat Hospital (Paris Cité University), he has consistently contributed to the advancement of respiratory medicine, particularly in the field of interstitial lung diseases (ILDs). His clinical insight, combined with a strong research portfolio, has positioned him as a prominent figure within the OrphaLung network. A dedicated family man with two children, Dr. Borie is widely respected for his integrity, leadership, and commitment to collaborative medicine. His career reflects a unique blend of academic excellence and impactful translational research, bridging the gap between genomics and clinical care in ILD. He is a registered member of the French Medical Council (Ordre des Médecins No. 75/71138), and his research has influenced European clinical guidelines and improved the understanding of rare genetic pulmonary conditions.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Robust Academic Background:
    Dr. Borie holds a PhD in Genetics, Master’s in Physiology, and HDR (habilitation to supervise doctoral research), which underlines his scientific credibility and ability to lead independent research.

  2. Clinical-Research Integration:
    As a University Professor and Hospital Practitioner, he merges frontline patient care with cutting-edge genetic and respiratory disease research.

  3. High Publication Impact:
    With 283 PubMed-indexed articles and an H-index of 60, Dr. Borie’s work demonstrates strong citation influence, indicating widespread recognition and utility in the scientific community.

  4. International Leadership:
    Active in multinational collaborations (e.g., OrphaLung, ERS), he has co-authored major position statements and clinical trials, influencing European respiratory care guidelines.

  5. Innovation in Rare Diseases:
    A recognized expert in familial interstitial lung disease and telomere disorders, his work has led to earlier diagnosis and targeted therapies—critical in fields where few experts exist.

  6. Recognition and Funding:
    He has secured prestigious mobility grants (ERS, Respirology Teachers College)—a marker of trust in his scientific mission and innovation.

🔍 Areas for Improvement:

  • Wider Public Health Translation: While Dr. Borie’s genomic research is exceptional, expanding into real-world health policy implementation could enhance systemic impact.

  • Patient Engagement & Advocacy: Developing patient-oriented tools or registries (e.g., digital apps or platforms for familial lung diseases) may broaden his outreach beyond academia and clinics.

  • Broader Visibility: Although highly cited in professional circles, participation in international keynote talks, editorial leadership, or mainstream health media could elevate his public and professional visibility.

🎓 Education:

Dr. Borie has pursued an extensive and rigorous academic path focused on respiratory and genetic medicine. He obtained his medical degree with specialization in Allergology and Immunopathology in 2006. A year earlier, in 2005, he earned a Master’s degree in Biology and Physiology of Circulation and Respiration. Demonstrating deep interest in genetics, he completed a PhD in Genetics in 2017, contributing significantly to our understanding of genetic underpinnings in pulmonary fibrosis. In 2019, Dr. Borie achieved the prestigious Habilitation à Diriger des Recherches (HDR) from the University of Paris 7, enabling him to supervise doctoral research. His academic background illustrates a powerful integration of clinical expertise and molecular research—providing him with the tools to lead innovative research projects at the intersection of genomics and pulmonology.

🩺 Experience:

Dr. Raphaël Borie has over 15 years of experience in respiratory medicine. From July 2011 to August 2020, he served as a Hospital Practitioner in the Pneumology Department at Bichat Hospital under Professors Aubier and Crestani. Since September 2020, he has been a University Professor Hospital Practitioner in the same department, affiliated with Paris Cité University. He has contributed to patient care, education of medical students and residents, and cutting-edge research. As part of the OrphaLung network, he plays a critical role in advancing diagnostic tools and treatment approaches for rare lung diseases. He is recognized for his collaborative leadership and interdisciplinary contributions across genetics, immunology, and pulmonology. His international collaborations and authorship of over 280 PubMed-indexed publications demonstrate his ongoing commitment to improving patient outcomes through translational research.

🏆 Awards and Honors:

Dr. Borie’s research excellence has been recognized through several prestigious awards and scholarships. In 2017, he received the European Respiratory Society (ERS) Mobility Grant for his work on Identification of Preclinical Markers of Pulmonary Fibrosis, supporting international collaboration and advanced training. The same year, he was also honored with the Respirology Teachers College Mobility Grant, reinforcing his pioneering research on early detection of fibrotic lung disease. His selection for these awards highlights both scientific innovation and dedication to knowledge exchange. His leadership in multi-center studies and involvement in ERS guideline statements further reflect his status as a thought leader in interstitial lung disease. These honors are a testament to his influence in shaping the future of pulmonary genetics and translational respiratory medicine.

🔬 Research Focus:

Dr. Raphaël Borie’s research centers on familial and genetic interstitial lung diseases, particularly the molecular mechanisms behind pulmonary fibrosis, telomere biology, surfactant-related gene variants, and early detection strategies. He works extensively on identifying genetic risk variants (e.g., MUC5B, DSP) and their implications in idiopathic pulmonary fibrosis. Through his participation in the OrphaLung network, he supports genomic screening for hereditary lung disorders and contributes to developing European guidelines. His work bridges genomic medicine and clinical pulmonology, aiming for earlier diagnosis and personalized treatment approaches. He has led and co-authored critical studies on RTEL1 mutations, telomerase complex defects, and familial ILD phenotypes, helping clinicians globally understand the heterogeneity and systemic implications of genetic lung disorders. His collaborative international research ensures his findings are applied in practice to optimize long-term patient care.

📚Publications Top Notes:

  • 🧬 High risk of lung cancer in surfactant-related gene variant carriers – Eur Respir J, 2024

  • 📄 European Respiratory Society Statement on Familial Pulmonary Fibrosis – Eur Respir J, 2022

  • 🧪 Colocalization of Gene Expression and DNA Methylation with Genetic Risk Variants – Am J Respir Crit Care Med, 2022

  • 🧬 RTEL1 mutations and their phenotypic variability – Eur Respir J, 2019

  • 💊 Safety and efficacy of pirfenidone in telomerase mutation carriers – Eur Respir J, 2018

  • 🌐 Diagnosis and follow-up of familial ILD: International survey – BMC Pulmonary Med, 2025

  • 🧬 New 2023 ACR/EULAR APS criteria performance in young patients – Letter, 2025

  • 🫁 A non-resolving cough: a case of familial pulmonary fibrosis – Breathe, 2025

  • 🧬 PFMG2025: Genomic medicine in French healthcare system – Review, 2025

  • 💊 Efficacy of CFTR modulators in ABCA3-deficiency ILD – Open Access, 2025

  • 🧠 Neurological manifestations in VEXAS syndrome – Journal of Neurology, 2025

  • 💉 Real-life use of PEXIVAS reduced-dose regimen in vasculitis – Ann Rheum Dis, 2025

  • 🧫 Recurrent respiratory papillomatosis with lung involvement – Eur Respir J, 2025

  • 🔍 RA-ILD: genetics to clinical overview – Review, 2025

  • 👶 Childhood ILD survivors in adulthood: European study – Eur Respir J, 2025

🧾 Conclusion:

Dr. Raphaël Borie exemplifies the ideal candidate for the Best Researcher Award. His excellence spans across clinical expertise, academic distinction, and international research leadership, especially in genetic and familial interstitial lung diseases—a field with enormous unmet need. His consistent scholarly output, impactful collaborations, and patient-focused studies highlight a unique blend of depth and innovation. While further expansion into public health frameworks and patient engagement tools would be valuable, his profile already reflects a world-class researcher with transformative contributions to pulmonary medicine.

Yang Liu | Cell Migration Studies | Best Researcher Award

Posted on by Cell Biologist

Prof. Dr. Yang Liu | Cell Migration Studies | Best Researcher Award

Prof. Dr. Yang Liu, Taiyuan University of Technology Institute of Biomedical Engineering CHINA, China

Dr. Yang Liu is an Associate Professor at the Institute of Biomedical Engineering, Taiyuan University of Technology, China. Since joining in 2013, Dr. Liu has focused on biomechanics, particularly the mechanical mechanisms involved in skin tissue damage and healing processes during traumatic events like burns and radiotherapy. Her interdisciplinary work bridges molecular, cellular, and tissue-level studies to better understand the interplay between mechanical factors and skin regeneration. Her research also extends into the development and structural optimization of biomedical materials such as tissue-engineered skins and advanced dressings. Dr. Liu has led several research and teaching reform projects, obtained a patent transformation, and contributed to national and provincial-level scientific investigations. Her innovative work in tissue engineering and skin trauma treatment continues to contribute significantly to biomedical science and material engineering.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Specialized Expertise
    Dr. Liu focuses on biomechanics in disease development, particularly related to cutaneous trauma (e.g., burns, radiotherapy), a niche but critical area in biomedical engineering.

  2. Material Innovation
    Her work in developing tissue-engineered skin and antibacterial dressings demonstrates applied innovation with potential clinical relevance.

  3. Project Leadership
    Successfully led and participated in multiple competitive research projects funded by national and provincial bodies, indicating trust in her scientific vision and capabilities.

  4. Research Productivity
    Though early in recognition, Dr. Liu has already co-authored several peer-reviewed journal articles in reputable publications like Scientific Reports and Placenta, which reflect growing academic contribution.

  5. Translational Research
    Her involvement in a patent achievement transformation shows a commitment to moving research beyond the lab into real-world applications.

🔧 Areas for Improvement:

  1. Citation Impact and Indexing
    The provided articles currently have 0 citations, and there is no citation index or h-index reported. Increasing publication visibility and citation impact should be a future focus.

  2. Global Recognition and Collaboration
    There is no mention of international collaboration, editorial roles, or professional memberships, which would enhance credibility and reach.

  3. Documented Industry Linkages
    Despite some project engagement with enterprises, more evidence of sustained industry partnerships or commercialization success would strengthen the application.

  4. Books, Patents, and Conferences
    Absence of published books, patents in process, or keynote roles in international conferences limits the academic portfolio breadth.

🎓 Education:

Although specific degree details are not listed, Dr. Yang Liu has built a strong academic foundation that supports her expertise in biomedical engineering and biomechanics. Her academic journey is closely aligned with her professional role at Taiyuan University of Technology, which is known for its technical research capabilities. Dr. Liu’s knowledge spans skin tissue biology, mechanical trauma, and biomedical materials science, indicating a background that likely includes degrees in biomedical engineering, bioengineering, or a related field. Her educational experience has equipped her with the skills necessary to conduct high-level research in skin regeneration, materials science, and tissue biomechanics. Additionally, her active participation in national scientific projects and her leadership in academic innovation at the university level point to rigorous formal training and ongoing academic development.

🧪 Experience:

Dr. Yang Liu has over a decade of professional experience in biomedical research since joining the Taiyuan University of Technology in 2013. Her work has revolved around exploring the mechanical and biological factors involved in traumatic skin injury and healing. She has successfully led and contributed to multiple projects, including those funded by the National Natural Science Foundation of China and enterprise collaborations. In addition to her scientific contributions, she has also directed teaching reform projects and a patent transformation, highlighting her dual commitment to both research and education. Her experience includes a strong focus on interdisciplinary collaboration across biology, materials science, and mechanical engineering. This breadth of experience has allowed her to develop innovative biomedical materials, such as tissue-engineered skin and functional skin dressings, aimed at improving clinical treatment outcomes for burn injuries and other trauma-related skin conditions.

🔬 Research Focus:

Dr. Yang Liu’s research centers on the biomechanics of skin tissue damage and healing, with an emphasis on cutaneous trauma from burns and radiotherapy. Her work investigates how mechanical forces impact skin at multiple biological levels—molecular, cellular, tissue, and animal models. A major portion of her research explores biomedical material innovation, particularly tissue-engineered skin, skin dressings, and antibacterial materials. She is particularly focused on understanding how structural and mechanical properties of these materials can improve therapeutic outcomes. Dr. Liu also studies oxidative stress, cell migration, and protein responses under mechanical pressure, making her work crucial to trauma therapy and regenerative medicine. With a patent transformation and multiple research projects to her credit, her research is positioned at the intersection of engineering innovation and clinical application, aiming to reduce complications in skin trauma treatment and enhance recovery efficiency through scientifically engineered materials.

📚 Publications Top Notes:

  1. 🧴🧬 Preparation and characterization of nano-silver/graphene oxide antibacterial skin dressing – Scientific Reports, 2025

  2. 🔬⛽ Experimental study on liquid products and pore structure characteristics of anthracite saturated by supercritical CO₂ – Gas Science and Engineering, 2025

  3. 🧠💥 The regulatory role of the nuclear scaffold protein Emerin on the migration of amniotic epithelial cells and oxidative stress in a pressure environment – Placenta, 2025

  4. 🛠️🔥 Annealing Response of Cold-rolled Ti₂AlNb Based Alloy Foil in Different Phase Regions – Tezhong Zhuzao Ji Youse Hejin (Special Casting and Nonferrous Alloys), 2025

📝 Conclusion:

Dr. Yang Liu shows significant promise as a biomedical researcher, with a clear, focused research trajectory, practical outputs (materials for skin regeneration), and consistent project engagement at institutional and national levels. While her global visibility and citation metrics are currently limited, her research has high translational potential in trauma medicine and biomedical materials, making her a strong emerging contender for the Best Researcher Award—especially under a category recognizing early- to mid-career researchers with impactful applied science work.

Zhijie Chang | Extracellular Vesicles | Cell Communication Award

Posted on by Cell Biologist

Prof. Zhijie Chang | Extracellular Vesicles | Cell Communication Award

Prof. Zhijie Chang, Tsinghua University, China

Professor Zhijie Chang is a distinguished molecular biologist and tenured professor at the School of Medicine and School of Life Sciences, Tsinghua University, Beijing. His research spans cancer signaling pathways, extracellular vesicle-mediated communication, and stem cell therapy, especially in lung diseases and tumor biology. A seasoned scholar, Dr. Chang earned his Ph.D. in Animal Genetics and Breeding before undertaking postdoctoral training at the University of Alabama at Birmingham. He is currently a respected editor of FEBS Letters and a leader in molecular oncology in China. His recent works highlight the role of CREPT, Smad signaling, and macrophage modulation in cancer and fibrosis. Through decades of academic and translational research, he has significantly advanced our understanding of cell communication in disease contexts. With an extensive publication record in top journals, Dr. Chang remains a leading figure in Asia’s biomedical research landscape.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Pioneering Contributions in Cell Communication
    Prof. Chang’s research on CREPT, Smad proteins, NF-κB/Nrf2, and BMP signaling has directly advanced the understanding of how intracellular and intercellular communication impacts disease progression, especially in cancer and pulmonary disorders.

  2. High-Impact Publications
    He has numerous peer-reviewed articles in prestigious journals such as Nature Communications, Molecular Cancer, Signal Transduction and Targeted Therapy, and Journal of Biological Chemistry, many of which explore molecular and cellular communication in cancer and tissue repair.

  3. Translational Focus
    His integration of mesenchymal stem cell therapy, extracellular vesicles, and gene therapy reflects a strong translational approach, applying basic science to therapeutic innovations—a critical criterion for this award.

  4. Scientific Leadership and Mentorship
    As a tenured professor at Tsinghua University and editor at FEBS Letters, Prof. Chang is a leader in biomedical research and scientific dissemination, actively contributing to academic growth and mentorship.

⚠️ Areas for Improvement:

  1. More Global Recognition
    While well-known in Chinese biomedical circles and respected internationally through publications, increased involvement in global consortia or leadership in international collaborations would further solidify his global scientific footprint.

  2. Public/Community Science Engagement
    Enhancing visibility through public lectures, science communication platforms, or policy advisory roles could broaden the societal impact of his work.

  3. Data-Sharing and Open Science Practices
    Encouraging or highlighting open-access datasets, repositories, or reproducible workflows would align with best practices in modern cell communication research.

🎓 Education:

Professor Zhijie Chang began his academic journey at Northwestern Agricultural University in Yangling, China, where he earned his B.Sc. (1978–1982) in Animal Science. He then continued at the same institution to obtain a combined M.Sc. and Ph.D. in Animal Genetics and Breeding from 1982 to 1989. His graduate research laid the foundation for his future in molecular biology, signaling studies, and genetics. Seeking international exposure and advanced training, he undertook postdoctoral research from March 1997 to October 1998 at the University of Alabama at Birmingham, USA, in the Department of Pathology. There, he specialized in the BMP signaling pathway, gaining expertise in molecular signaling processes critical to cell communication. This blend of domestic and international education has equipped Dr. Chang with both the technical rigor and global perspective needed to pioneer breakthroughs in biomedical science.

💼 Professional Experience:

Professor Zhijie Chang has held a full professorship at Tsinghua University’s School of Medicine since June 2005, where he investigates cancer-related signaling mechanisms. Before this, he completed postdoctoral research at the University of Alabama at Birmingham, focusing on BMP signaling, which strengthened his understanding of developmental and pathological cell signaling. Over the years, he has built a highly productive research lab, contributed extensively to translational medicine, and trained numerous doctoral and postdoctoral researchers. As an editor of FEBS Letters, he also contributes to scientific publishing and peer-review processes. His roles across academia, research, and editorial boards mark him as a multifaceted scientist whose work bridges laboratory insights and therapeutic applications. His collaborative style and consistent research funding reflect his leadership and innovation in molecular oncology and regenerative medicine.

🏅 Awards and Honors:

Professor Zhijie Chang has been recognized multiple times by the Chinese Cell Biology Society for his high-impact publications. In 2003, he received the First Merit Paper Award for his groundbreaking research on hSef-mediated MAPK signaling inhibition in J. Biol. Chem. In 2005, he earned the Third Merit Paper Award for his study on CHIP-mediated degradation of Smad proteins, published in Mol. Cell. Biol.. These awards underscore his early and sustained contributions to deciphering molecular signaling pathways involved in cell communication, differentiation, and oncogenesis. His recent recognitions include publications in top-tier journals like Nature Communications, Molecular Cancer, and Signal Transduction and Targeted Therapy, indicating the continued relevance and innovation of his work. His role as an editor for FEBS Letters further highlights his stature in the field and dedication to advancing cell biology research at national and international levels.

🔬 Research Focus:

Dr. Zhijie Chang’s research primarily investigates cellular communication in cancer and inflammatory diseases, with a focus on CREPT, Smad proteins, and extracellular vesicles. His work dissects how tumor-derived signals modulate the tumor microenvironment, metastasis, and immune cell behavior. He has made critical discoveries regarding the role of CREPT in chromatin looping and transcriptional regulation, especially in triple-negative breast cancer. In pulmonary fibrosis models, he has shown how umbilical cord-derived mesenchymal stem cells (MSCs) modulate macrophage activity via secreted vesicles. Another major area is his exploration of Smurf1, PDK1–Akt, and JAK/STAT3 signaling axes, targeting them for therapeutic intervention in various cancers. His translational approach integrates gene therapy, stem cell-based treatments, and protein signaling studies, bridging basic and clinical sciences. Through collaborative and interdisciplinary methods, Dr. Chang contributes valuable insights into how cells communicate and respond in disease settings.

📚 Publication Top Notes:

  1. 📘 CREPT is required for the metastasis of triple-negative breast cancer through a co-operational-chromatin loop-based gene regulation

  2. 🧪 Clinical investigation on nebulized human umbilical cord MSC-derived extracellular vesicles for pulmonary fibrosis treatment

  3. 🧬 Gene Therapy with Enterovirus 3C Protease: A Promising Strategy for Various Solid Tumors

  4. 🌬 Umbilical cord-derived mesenchymal stem cells preferentially modulate macrophages to alleviate pulmonary fibrosis

  5. ⚡ CREPT upregulates the antioxidant genes via activation of NF-κB/Nrf2 in acute liver injury

  6. 🔁 An oncoprotein CREPT functions as a co-factor in MYC-driven transformation and tumor growth

  7. 🎯 Targeting Smurf1 to block PDK1–Akt signaling in KRAS-mutated colorectal cancer

  8. 📤 Microenvironment-induced CREPT expression by cancer-derived small extracellular vesicles primes field cancerization

  9. 🔋 Oxidative phosphorylation safeguards pluripotency via UDP-N-acetylglucosamine

  10. 🍄 Lachnochromonin, a fungal metabolite from Lachnum virgineum, inhibits cell growth and promotes apoptosis in tumor cells through JAK/STAT3 signaling

🧾 Conclusion:

Professor Zhijie Chang exhibits a robust and well-established career built on investigating mechanisms of cell signaling, tumor microenvironment dynamics, and intercellular communication. His scientific rigor, translational impact, and leadership in the field of cell communication make him an outstanding candidate for the Research for Cell Communication Award. Addressing some broader outreach and open science practices could further elevate his profile, but his contributions to foundational and applied research in this domain are already exemplary.

Chenlong YANG | Cancer Cell Biology | Best Researcher Award

Posted on by Cell Biologist

Prof. Chenlong YANG | Cancer Cell Biology | Best Researcher Award

Prof. Chenlong YANG, Peking University Third Hospital, China

Dr. Chenlong Yang, M.D., Ph.D., is an accomplished neurosurgeon and research associate professor at the Department of Neurosurgery, Peking University Third Hospital. With over 15 years of clinical and research experience, he specializes in neuro-oncology, spinal neurosurgery, and translational neuroscience. Dr. Yang earned his M.D. from Shandong University and his Ph.D. in Neurological Surgery from Capital Medical University. He has trained and worked in prestigious institutions including Beijing Tiantan Hospital and the State Key Laboratory of Vascular Homeostasis and Remodeling. He has contributed significantly to advancements in brain tumor diagnostics, neuroimmunology, and surgical innovations, with numerous high-impact publications. Recognized internationally, he frequently presents at top neurosurgical conferences such as EANS and the Japan-China Neurosurgery Alliance. His research bridges basic science and clinical neurosurgery, aiming to improve surgical precision and therapeutic outcomes. Dr. Yang is also known for his leadership in collaborative, multidisciplinary research teams.

Publication Profile: 

Google Scholar

✅ Strengths for the Award:

  1. 📚 Robust Academic and Clinical Training

    • Earned an M.D. from Shandong University and a Ph.D. in Neurological Surgery from Capital Medical University.

    • Completed clinical training at Beijing Tiantan Hospital, a top-tier neurosurgical institution in China.

  2. 🔬 Multidisciplinary and Translational Research Excellence

    • His research spans neuro-oncology, neuroimmunology, spinal neurosurgery, and advanced neuroimaging.

    • Conducted preclinical work on Alzheimer’s disease models and neuroprotection, along with current research in immune checkpoint therapy and intraoperative imaging.

  3. 📈 High-Impact Publications

    • Over 20 peer-reviewed publications in journals such as Scientific Reports, J Exp Clin Cancer Res, Neurosurgical Review, and Biophysical Journal.

    • His research on chordomas, gliomas, and spinal tumors has significantly contributed to the field.

  4. 🌍 International Recognition

    • Speaker at major international conferences like EANS 2025 and KSNS 2024.

    • Previously awarded a scholarship by the Turkish Neurosurgical Society.

  5. 🤝 Leadership in Collaboration

    • Plays a key role at the Center for Precision Neurosurgery and Oncology and the State Key Laboratory of Vascular Homeostasis and Remodeling, fostering interdisciplinary collaborations across neurosurgery, imaging, and immunotherapy.

  6. 🎯 Focus on Precision and Innovation

    • Pioneering high-resolution MRI techniques, fluorescent intraoperative navigation, and predictive modeling for neurosurgical outcomes.

🔄 Areas for Improvement:

  1. 📊 Independent Research Lead

    • While he has several corresponding author papers, increasing his share of first-author or sole-PI grants would further elevate his research identity.

  2. 🌐 Global Collaborations

    • Though he has spoken at international conferences, expanding collaborative projects with leading global neuroscience centers could amplify impact.

  3. 💡 Technology Commercialization

    • Given his innovation in imaging and diagnostics, pursuing intellectual property rights or translational funding (e.g., for clinical tools or surgical systems) could be a valuable next step.

  4. 📄 Diversification of Research Outputs

    • A few review articles and meta-analyses would strengthen his role as a thought leader and field synthesizer.

📘 Education:

Dr. Yang pursued his foundational medical education at Shandong University, earning an M.D. in Clinical Medicine (2006–2011). This training provided a solid clinical base and early exposure to neurology and internal medicine. He then advanced to a doctoral program at Capital Medical University, Beijing (2011–2017), earning his Ph.D. in Neurological Surgery. During his Ph.D., he received specialized training in neurosurgical techniques and engaged in cutting-edge research, particularly focusing on neuro-oncology and degenerative neural diseases. As part of his early research career, he also worked at the Institute of Neurobiology, Shandong University, investigating neuroprotective agents and Alzheimer’s disease models. Dr. Yang’s academic journey is characterized by rigorous clinical training and scientific inquiry, equipping him with the knowledge and skills essential for bridging the gap between the lab bench and the operating room. His education laid a strong foundation for his future contributions to precision neurosurgery and translational neuroscience.

💼 Experience:

Dr. Yang has over a decade of diversified experience across top medical and research institutions. He currently serves as a Research Associate Professor and Attending Physician at the Department of Neurosurgery, Peking University Third Hospital (2020–present), where he leads several clinical and translational research projects. Prior to this, he completed a postdoctoral fellowship (2017–2020) in the Department of Orthopedics at the same hospital, emphasizing spinal and neuro-oncologic conditions. From 2011 to 2017, he worked as a resident in Neurosurgery at Beijing Tiantan Hospital, one of China’s premier neurosurgical centers, gaining extensive experience in surgical treatments and neurovascular procedures. His roles span clinical surgery, research coordination, and academic instruction. Additionally, he actively contributes to the Center for Precision Neurosurgery and Oncology and the State Key Laboratory of Vascular Homeostasis and Remodeling, leading initiatives to improve patient outcomes through interdisciplinary innovations in neurosurgical care.

🧠 Research Focus:

Dr. Chenlong Yang’s research integrates neurosurgery, oncology, immunology, and biomedical engineering. His primary focus lies in neuro-oncology, with a strong emphasis on chordoma biology, glioma immunotherapy, and molecular diagnostics. He explores immune checkpoint therapies, tumor microenvironment modulation, and the development of predictive models for neurosurgical complications such as postoperative delirium. Dr. Yang is also deeply involved in technological innovation in neurosurgery, investigating intraoperative fluorescence imaging, high-resolution MRI, and minimally invasive spinal techniques. His work on spatial learning, Alzheimer’s models, and neuroprotection during his early career continues to inform his translational research. He collaborates across disciplines, from molecular biologists to radiologists, aiming to build precision-guided therapeutic frameworks. His research is extensively published in journals like Scientific Reports, J Exp Clin Cancer Res, and Frontiers in Neurology. Through this work, Dr. Yang seeks to advance the standard of care in neurosurgical oncology and promote patient-specific interventions.

📚 Publication Top Notes:

  1. 🧬 SMARCB1 orchestrates cellular plasticity and oncogenic pathways in typical and chondroid chordomas

  2. 🛡️ Cracking Chordoma’s Conundrum: Immune Checkpoints Provide a Potential Modality

  3. 🌱 From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms – a review

  4. 💡 Intraoperative fluorescence redefining neurosurgical precision

  5. 🧠 The evolution and integration of technology in spinal neurosurgery: A scoping review

  6. 👁️ Single-cell transcriptomic atlas of aging macaque ocular outflow tissues

  7. 🧮 Risk stratification and predictive modeling of postoperative delirium in chronic subdural hematoma

  8. 📶 Characteristic fingerprint spectrum of α-synuclein mutants on terahertz time-domain spectroscopy

  9. 🐒 Normative profile of retinal nerve fiber layer thickness in cynomolgus monkeys

  10. 🌀 Accurate diagnosis and treatment of sacral meningeal cysts using high-resolution MRI

  11. 🧪 Intraspinal hemangioblastomas: analysis of 92 cases in a single institution

🏁 Conclusion:

Dr. Chenlong Yang exemplifies the ideal profile of a cutting-edge clinician-scientist, merging neurosurgical precision with immunological insight and technological innovation. His commitment to patient-centered research, consistent academic output, and recognition on international platforms underscores his eligibility for the Best Researcher Award. With continued growth in independent leadership and global research impact, Dr. Yang is not only a deserving candidate now but is poised to become a prominent global figure in neurosurgical research in the years to come.

Marcos Jessé Abrahão Silva | Cell Biology | Best Researcher Award

Posted on by Cell Biologist

Mr. Marcos Jessé Abrahão Silva | Cell Biology | Best Researcher Award

Mr. Marcos Jessé Abrahão Silva, State University of Pará (UEPA), Brazil

Marcos Jessé Abrahão Silva is a Brazilian biomedical scientist and Ph.D. student at the State University of Pará (UEPA), specializing in immunogenetics and molecular biology. He holds a Bachelor’s in Biomedicine from UNAMA and a Master’s in Epidemiology and Health Surveillance from the Evandro Chagas Institute. Marcos has contributed to over 35 technical-scientific publications, including high-impact journals such as Frontiers in Immunology and Microorganisms, and has accumulated more than 260 citations. He’s a published author of multiple scientific books and a reviewer for prestigious journals like Current Microbiology. His research spans infectious diseases like COVID-19, leprosy, HIV, and bacterial resistance. As a member of Sigma Xi, his academic dedication has earned him editorial appointments and international collaborations, including with Tulane University. Currently, Marcos leads research on HIV prevention in vulnerable groups using innovative approaches via social media under the project “raprev.aids”.

Publication Profile:

Google Scholar

✅ Strengths for the Award:

  1. Strong Publication Record 📚
    Marcos has authored or co-authored over 35 scientific publications, with more than 20 in high-impact journals (JCR indexed) such as Frontiers in Immunology, Viruses, Microorganisms, and Genes—an exceptional record for a Ph.D. student.

  2. Global Citation Impact 🌍
    His Google Scholar h-index of 7, Scopus h-index of 7, and Web of Science h-index of 6—along with 260+ citations—reflect international academic recognition and influence.

  3. Multidisciplinary Research Expertise 🧬
    His work integrates epidemiology, immunogenetics, molecular biology, and bioinformatics, focusing on infectious diseases including COVID-19, HIV, leprosy, and paracoccidioidomycosis, which are highly relevant to global health.

  4. Editorial and Peer-Review Roles ✍️
    Marcos is a reviewer for top journals, including CURRENT MICROBIOLOGY, and serves on the editorial board of the International Journal of Genetics—demonstrating leadership in academic publishing.

  5. International and Institutional Collaboration 🤝
    He collaborates with respected institutions like Evandro Chagas Institute, Federal University of Ceará, and Tulane University, expanding the impact of his research across borders.

  6. Innovation in Health Communication 💡
    He is currently leading a social innovation project (raprev.aids) combining science, technology, and culture for HIV prevention among vulnerable populations using digital and artistic media—a model for translational science.

⚠️ Areas for Improvement:

  1. First-Author Leadership in Top-Tier Journals
    While co-authorship is strong, more consistent first-author publications in Q1 journals would further solidify his leadership in research.

  2. Patent Contributions & Industry Linkages
    Although experienced in academic research, strengthening links with biomedical industry or technology transfer (patents) could amplify his societal and commercial impact.

  3. Global Networking
    Participation in more international conferences or fellowships would further raise his visibility on the global scientific stage.

🎓 Education0:

Marcos Jessé Abrahão Silva’s academic foundation is rooted in Biomedicine, having completed his Bachelor’s degree at the University of the Amazon (UNAMA) from 2018 to 2021. Following this, he earned his Master of Science degree from the prestigious Evandro Chagas Institute (IEC) through the Postgraduate Program in Epidemiology and Health Surveillance (2021–2023). He is currently pursuing his Ph.D. in Parasitology Biology in the Amazon at the State University of Pará (UEPA). Additionally, he is specializing in Bioinformatics at the Federal Technological University of Paraná (UTFPR), expected to complete in 2025. His educational trajectory reflects a strong emphasis on translational research, infectious disease epidemiology, and molecular diagnostics. Marcos has also been inducted as an official member of Sigma Xi, The Scientific Research Honor Society, highlighting his academic and professional distinction. His interdisciplinary education supports his work in cutting-edge biomedical and public health research.

🧪 Experience:

Marcos Jessé has developed extensive research experience in immunogenetics, molecular biology, and epidemiology. He has actively participated in significant research projects, such as the Hansen’s Immunogenetic Study and COVID-19 response analysis in Brazil. Marcos has co-authored more than 35 scientific publications, including international peer-reviewed journals, and written chapters in academic books on infectious diseases. His roles have included principal investigator, project member, and scientific reviewer for journals like Current Microbiology. He also has experience in scientific consulting and is involved in translational research, particularly focusing on disease susceptibility genetics. Marcos collaborates with leading institutions like the Evandro Chagas Institute, Federal University of Ceará, and Tulane University. Beyond academic research, he contributes to community-based health innovation through HIV prevention projects involving social media outreach. He has served in editorial roles and has been recognized with international awards for his scientific contributions, making him a standout emerging researcher from the Global South.

🔍 Research Focus:

Marcos Jessé Abrahão Silva’s research centers on immunogenetics, infectious diseases, and molecular biology, with a special emphasis on diseases endemic to Brazil and the Amazon. He investigates the genetic factors influencing susceptibility to pathogens like Mycobacterium leprae, HIV-1, and SARS-CoV-2, often analyzing Single Nucleotide Polymorphisms (SNPs) and immune response mechanisms. His work aims to unravel how innate and adaptive immune pathways contribute to disease severity, particularly in viral and bacterial infections. Marcos has conducted systematic reviews and meta-analyses to clarify the epidemiological role of genetic polymorphisms. His recent focus includes a culturally innovative HIV prevention project, “raprev.aids,” integrating artistic and scientific communication via social networks. He is also active in studying antimicrobial resistance, such as in Pseudomonas aeruginosa. His research goal is to bridge laboratory science with public health practice, particularly in vulnerable populations across the Amazon and broader Latin America.

📚 Publications Top Notes:

  1. 🧫 Hyperinflammatory response in COVID-19: a systematic review – Viruses

  2. 🧠 Adaptive immunity to SARS-CoV-2 infection: A systematic review – Frontiers in Immunology

  3. 🧬 Innate immunity to SARS-CoV-2 infection: a review – Epidemiology & Infection

  4. 🧪 The Relationship between TLR3 rs3775291 Polymorphism and Infectious Diseases: A Meta-Analysis – Genes

  5. 🧫 The Association between CCL5/RANTES SNPs and Susceptibility to HIV-1 Infection: A Meta-Analysis – Viruses

  6. 🧬 The relationship between 896A/G (rs4986790) polymorphism of TLR4 and infectious diseases: A meta-analysis – Frontiers in Genetics

  7. 🦠 Endemic High-Risk Clone ST277 & SPM-1-Producing P. aeruginosa During COVID-19 in Brazil – Microorganisms

  8. 🧫 Prevalence of MβL-Producing P. aeruginosa in Brazil: A Meta-Analysis – Microorganisms

  9. 🐀 The Presence of Mycobacterium leprae in Wild Rodents – Microorganisms

  10. 🧬 Associations between TLR3 SNPs and COVID-19 in Belém-PA Professionals – Frontiers in Cellular and Infection Microbiology

🔍 Conclusion:

Marcos Jessé Abrahão Silva is an exceptionally promising early-career researcher whose contributions already surpass many peers at the same academic stage. His proven scientific output, international citation record, and commitment to public health innovation make him highly suitable for the Best Researcher Award. His research not only addresses local health challenges in the Amazon and Brazil but also contributes meaningfully to the global understanding of infectious diseases and immune responses.

Veronica Gagliardi | microcirculation | Best Researcher Award

Posted on by Cell Biologist

Dr. Veronica Gagliardi | microcirculation | Best Researcher Award

Dr. Veronica Gagliardi, Università degli studi di Padova, Italy

Dr. Veronica Gagliardi is an Italian Medical Doctor specializing in Anaesthesiology, Resuscitation, Intensive Care, and Pain Therapy. Born on August 22, 1996, in Spinea (VE), she is currently undergoing advanced clinical training at the University of Padua, where she has also undertaken a Level II Master in multimodal cardiac imaging. She combines academic excellence with frontline clinical experience in major regional hospitals, including Ospedale dell’Angelo in Mestre and Policlinico Universitario di Padova. Her work focuses on intensive care medicine, advanced echocardiography, and non-invasive ventilation strategies. Dr. Gagliardi is widely published, with a strong record in critical care, pain therapy, and ultrasound techniques. Her proactive involvement in clinical research and innovative therapies, including ECMO and auricular acupuncture, reflects a strong commitment to scientific advancement in patient care. She is a promising researcher and clinician, striving to integrate cutting-edge evidence with compassionate care.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Extensive Research Portfolio:
    Dr. Gagliardi has authored and co-authored over 10 peer-reviewed publications across respected international journals (Life, Medicina, Critical Care, Cureus, EJTM, Arch Clin Biomed Res), covering high-impact areas like ECMO, microcirculation, pain therapy, and non-invasive ventilation.

  2. Clinical-Research Integration:
    Her ability to bridge clinical practice and research is a standout quality. From ECMO and PEEP titration in COVID-19 to auricular electroacupuncture and ultrasound-guided pain procedures, she applies science directly to bedside care.

  3. Strong Academic Record:
    With a Medical Degree cum laude (110/110) and advanced training at the University of Padua, she demonstrates academic excellence, now furthered by a Level II Master in echocardiographic imaging.

  4. Leadership and Collaboration:
    She has actively participated in multi-center projects and international symposia, indicating both team leadership and scientific communication skills.

  5. Innovation and Versatility:
    Her research includes novel and multidisciplinary approaches—like capsaicin patch use for neuropathic pain and auricular diagnostics in oncology contexts.

⚙️ Areas for Improvement:

  1. Recognition and Awards:
    While her work is highly impactful, Dr. Gagliardi may benefit from more formal recognition, such as national/international fellowships, grants, or young investigator awards.

  2. Independent Research Funding:
    Securing her own research grants in the near future would further strengthen her research independence and global visibility.

  3. Broader Dissemination:
    Increasing her presence through conference presentations, keynote talks, or editorial roles would amplify the visibility of her work and boost her academic footprint.

🎓 Education:

Dr. Veronica Gagliardi earned her Master’s Degree in Medicine and Surgery with 110/110 with Honours from the University of Padua, completing an experimental thesis under Prof. Paolo Navalesi on respiratory failure in COVID-19 patients. Since November 2021, she has been enrolled in a five-year residency program in Anaesthesiology, Resuscitation, Intensive Care, and Pain Therapy at the same institution, with rotations in several prominent hospitals. Starting November 2024, she will also undertake a Level II Master (ESTAV) in stress echocardiography, advanced transesophageal, and multimodal cardiac imaging, focusing on perioperative and interventional cardiac ultrasound techniques. Her education reflects not only clinical rigor but also a keen interest in research and innovation, particularly in areas like non-invasive ventilation, ultrasound diagnostics, and pain modulation. Her academic background is complemented by strong scientific output and peer-reviewed contributions in high-impact journals.

💼 Professional Experience:

Dr. Gagliardi has held the role of Medical Doctor specializing in Anaesthesiology and Intensive Care at Ospedale dell’Angelo in Mestre, starting in January 2025. Initially assigned to general anaesthesiology (UOS), she has since progressed to the Cardiac Intensive Care Unit (UOS) from May 2025. Her residency training from November 2021 to January 2025 included rotations in premier institutions such as Policlinico Universitario di Padova, Ospedale S. Antonio, Ospedale Ca’ Foncello, and Ospedale SS Giovanni e Paolo, gaining experience in critical care, pain therapy, perioperative medicine, and emergency interventions. Throughout her career, she has consistently demonstrated clinical versatility, excelling in high-pressure ICU settings. She combines clinical competence with advanced procedural skills, including echocardiography and ultrasound-guided regional blocks. This diverse clinical exposure underpins her contribution to complex case management and patient-centered care.

🏅 Awards and Honors:

Dr. Veronica Gagliardi has not been explicitly listed with specific awards, but her academic and research profile clearly reflects recognition-worthy achievements. She graduated with honors (110/110 cum laude) in Medicine, which stands as an early testament to her dedication and excellence. Her first-author publications in indexed journals, such as Life, Medicina, Critical Care, and EJTM, highlight her as a leading contributor to translational and clinical research in anesthesiology and critical care. Her participation in international symposiums, including the 40th International Symposium on Intensive Care & Emergency Medicine, and collaborations with established experts like Prof. Navalesi, further underscore her growing reputation. While formal honors such as Best Researcher Awards are yet to be listed, her CV is aligned with the standards of excellence and would merit such recognition in academic and clinical research circles.

🔬 Research Focus:

Dr. Gagliardi’s research is deeply rooted in critical care medicine, with a strong emphasis on microcirculation, non-invasive ventilation, pain management, and echocardiographic imaging. Her work spans experimental and clinical domains—from animal models exploring systemic morphine’s anti-inflammatory effects, to human studies on ECMO efficiency and caudal epidural injections. She has delved into innovative diagnostics like diaphragm ultrasound for predicting extubation outcomes, and non-conventional therapies such as auricular electro-acupuncture for microcirculatory modulation. Her research extends into the perioperative and post-operative use of non-invasive respiratory support, and stress echocardiography, bridging imaging and intensive care management. She actively collaborates on multi-center reviews and pilot studies, showing both independence and teamwork. Dr. Gagliardi’s research consistently aims at improving patient outcomes through evidence-based and minimally invasive approaches, contributing significantly to the evolving landscape of modern anaesthesia and critical care.

📚 Publications Top Notes:

📄 The Effects of Levosimendan on Microcirculation and Peripheral Perfusion in Septic Shock: A Pilot Study
📄 Recirculation in Veno-Venous Extracorporeal Membrane Oxygenation
📄 A Possible Correlation Between Auricular Angiomas and Breast Cancer Through Auricular Acupuncture Diagnosis: An Observational Case-Control Study
📄 Ultrasound-guided caudal epidural injection to treat symptoms of lumbar spinal stenosis: a retrospective study
📄 Effects of noninvasive respiratory support in post-operative patients: a systematic review and network meta-analysis
📄 Systemic Morphine but Not Local Administration Shows Preventive Anti-Inflammatory Effect in a Rat Model of Capsaicin-Induced Paw Edema
📄 Effect of Low- and High-Frequency Auricular Stimulation with Electro-Acupuncture on Cutaneous Microcirculation: A Cross-Over Study in Healthy Subjects
📄 Diaphragm Ultrasound: A Valuable Predictor of the Outcome of Extubation. An Observational Pilot Study in Covid-19 Related ARDS
📄 Persistent neuropathic pain treated with Capsaicin patches: a novel promising approach
📄 P101 Execution of percutaneous dilatational tracheostomy using the standard laryngeal mask airway for ventilation: a prospective survey study
📄 Positive end-expiratory pressure titration in COVID-19 acute respiratory failure: electrical impedance tomography vs. PEEP/FiO2 tables

🧾 Conclusion:

Dr. Veronica Gagliardi is an exceptional emerging researcher who combines clinical acumen with a robust scientific mindset. Her research is innovative, clinically relevant, and methodologically sound, spanning critical areas like sepsis management, ECMO, echocardiography, and noninvasive ventilation strategies.

Yong-Soo Bae | Immunology Cellular Interactions | Best Researcher Award

Posted on by Cell Biologist

Prof. Dr. Yong-Soo Bae | Immunology Cellular Interactions | Best Researcher Award

Prof. Dr. Yong-Soo Bae | Sungkyunkwan University | South Korea

Dr. Yong-Soo Bae is a distinguished immunologist and professor at the Department of Biological Science, Sungkyunkwan University, Korea. He currently serves as the Director of the SRC Center for Immune Research on Non-lymphoid Organs (CIRNOS). With over three decades of academic, clinical, and industry experience, Dr. Bae is internationally recognized for his pioneering research in immunology, virology, and vaccine development. His multidisciplinary contributions span academia, biotech innovation (as CEO/CTO of JW Creagene Inc.), and scientific leadership, including organizing global conferences and serving as editor-in-chief and president in numerous societies. His work focuses on immune modulation, cancer immunotherapy, and mucosal vaccines, which has led to influential publications in prestigious journals like Nature Communications, Science Advances, and Advanced Materials. Dr. Bae’s career reflects a commitment to innovation, collaboration, and education, making him a strong candidate for the Best Researcher Award.

Publication Profile:

Scopus

✅ Strengths for the Award

  1. Pioneering Research Leadership
    Dr. Bae has led groundbreaking research in immunology, particularly in immune regulation of non-lymphoid organs, vaccine development, and cancer immunotherapy. His leadership of the Center for Immune Research on Non-lymphoid Organs (CIRNOS) demonstrates his national influence in immune research.

  2. Extensive Scientific Contributions
    With over 18 high-impact publications in the past 3–4 years alone, including in top-tier journals like Nature Communications, Molecular Therapy, Science Advances, and Advanced Materials, Dr. Bae continues to push the boundaries of translational immunology and personalized medicine.

  3. International & Interdisciplinary Experience
    His training at Harvard Medical School, his professorships across Korean institutions, and leadership at JW Creagene Inc. showcase both academic and industrial impact.

  4. Scientific Community Engagement
    Roles such as Editor-in-Chief, society president, and organizer of global conferences (e.g., DC2012) reflect his commitment to advancing scientific dialogue and collaboration.

  5. Mentorship and Institutional Development
    Dr. Bae has contributed significantly to capacity building in Korea’s biomedical research landscape, mentoring junior scientists and shaping departmental growth.

⚠️ Areas for Improvement:

  1. Global Collaboration Visibility
    While his work is highly impactful in Korea and Asia, more joint publications with global institutions (e.g., NIH, Oxford, Karolinska) could further enhance international research influence.

  2. Patent and Commercial Output Reporting
    As former CEO/CTO of JW Creagene, elaborating on patented innovations or therapeutic products brought to market would strengthen the case for translational impact.

  3. Formal Recognition or Awards
    Inclusion of formal honors (e.g., national science medals, international society awards) would help quantify his recognition outside Korea.

  4. Consistent Author Disambiguation
    In some publications, author names appear as “Y.S. Bae” or “Yong-soo Bae.” Consistent use of a standardized author name across indexing platforms would help centralize his citation metrics and scholarly footprint.

 

🎓 Education:

Dr. Yong-Soo Bae’s academic journey began with a Bachelor’s and Master’s degree in Microbiology from Seoul National University in 1981 and 1983, respectively. His foundational training in microbiology laid the groundwork for his research trajectory in infectious disease and immunology. He earned his Ph.D. in 1990 from the University of Calgary, Alberta, Canada, in the Virology Division of the Department of Microbiology and Infectious Diseases, Faculty of Medicine. His doctoral research was crucial in shaping his interest in host-pathogen interactions and immune regulation. Dr. Bae’s international education experience has enabled him to blend Western and Eastern biomedical research paradigms, contributing to his ability to lead collaborative global projects and initiatives in immunotherapy and vaccine innovation.

💼 Experience:

Dr. Yong-Soo Bae’s professional career spans academia, research, and biotech leadership. He completed a postdoctoral fellowship at Dana-Farber Cancer Institute, Harvard Medical School (1991–1993), which enriched his expertise in cancer immunology. He held professorial roles at Hannam University (1993–2003) before joining Sungkyunkwan University in 2004, where he later became Department Chair and Distinguished Professor. Dr. Bae also served as Director of CIRNOS (2017–2024) and led JW Creagene Inc. as CEO/CTO (1998–2015), bridging science and industry. His editorial and leadership roles include Editor-in-Chief of the Journal of Bacteriology and Virology, President of the Korean Society of Virology, and Vice President of the Korean Vaccine Society. His diverse roles demonstrate a unique blend of academic excellence, organizational leadership, and translational research expertise.

🔍 Research Focus:

Dr. Yong-Soo Bae’s research focuses on innate and adaptive immune regulation, tumor immunology, mucosal immunotherapy, and vaccine delivery. He investigates cellular interactions in the immune microenvironment, with particular attention to innate lymphoid cells (ILCs), neutrophils, and dendritic cells. His translational work includes novel vaccine platforms, epitranscriptomics, immune checkpoint modulation (e.g., CISH, PD-1), and cell therapy for diseases such as asthma, leukemia, and cancer. He also explores microbiome-immune crosstalk and inflammation-related organ damage (e.g., renal fibrosis, lung inflammation). His group has published extensively on m6A modifiers, microRNAs, and innovative delivery systems like gel-to-nanovaccines. His latest studies dive into immunometabolism and the interplay between immune cells and tissue repair, offering groundbreaking insights for future immunotherapies. Dr. Bae’s work is highly cited and remains at the forefront of immune system-based therapeutic innovation.

📚 Publications Top Notes:

  1. 📘 Therapeutic Potential of microRNA Against Th2-associated Immune Disorders – Current Topics in Medicinal Chemistry (2021)

  2. 💉 COVID-19 Vaccines and Oral-Mucosal Vector System as a Potential Vaccine Platform – Vaccines (2021)

  3. 🧬 Immunotherapeutic Potential of m6A-Modifiers and microRNAs in AML – Biomedicines (2021)

  4. 🎯 Epitranscriptomic Approach to Improve ICB Therapy by Targeting CISH – Cells (2021)

  5. 🧫 TFH-B-TRM Dysregulation and Anti-PD-1 Responses in EGFR-mutant Lung Cancer – Nature Communications (2021)

  6. 🧪 Adenoviral CD200R-Ig Enhances Antitumor Immunity via M2 Macrophage Inhibition – Molecular Therapy

  7. 🌫 Air Pollutant-induced Neutrophils Worsen Airway Inflammation – JACI (2021)

  8. 🦠 NCR+ILC3s and the Microbiome in Asthma Severity – Immune Network (2021)

  9. 📖 Advances in Personalized Therapy for AML by Targeting Intracellular Checkpoints – eBook Chapter (2021)

  10. 🧵 Siglec-F Neutrophils Drive Fibrosis in Renal Disease – JCI (2022)

🧾 Conclusion:

Dr. Yong-Soo Bae is an exceptional and highly deserving candidate for the Best Researcher Award. His contributions over four decades span foundational research, translational innovation, academic leadership, and scientific diplomacy. The depth of his scientific output, particularly in immunology, epigenetics, and vaccine development, is matched by his long-term commitment to mentoring, editorial work, and building research institutions in Korea.While enhancing his global recognition and expanding international collaborative outputs could further elevate his status, Dr. Bae’s consistent high-impact contributions, research leadership, and policy involvement clearly position him as a top-tier researcher in the life sciences.